PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Vicore and Endeavor’s therapies show promise in treating IPF

Both drugs have the potential to offer a disease-modifying approach to the lung disease.

Vicore Pharma and Endeavor BioMedicines have shared new data from two mid-stage clinical trials of two therapies that show promise in treating patients living with idiopathic pulmonary fibrosis (IPF).

Vicore’s buloxibutid and Endeavor’s ENV-101 could provide new ways of treating this chronic, progressive lung disease.

Affecting up to 20 people per 100,000 globally, IPF is a rare lung disease that causes the lungs to thicken and stiffen, causing permanent fibrosis and difficulty breathing.

Both treatments are being investigated to improve on the current standard-of-care therapies for IPF that could potentially slow the decline of lung function, without reversing or stopping it.

In a phase 2a AIR trial, buloxibutid, an angiotensin II type 2 receptor agonist taken orally twice a day, showed significantly improved lung function across 36 weeks with an average forced vital capacity (FVC) increase of 216ml from baseline, reversing the 180ml decline over the same period that would usually be observed in untreated IPF patients.

In addition, the drug was safe and well-tolerated over the 26-week period of treatment, with no new drug-related adverse events.

Meanwhile, Endeavor’s hedgehog (Hh) signalling pathway inhibitor presented data from another phase 2a trial, which showed that ENV-101 achieved a statistically significant increase in total lung capacity above baseline at 12 weeks, with an average 200ml improvement compared to a decrease of 56ml in an IPF group treated with placebo.

Usually involved in wound healing, the Hh pathway is thought to be activated in IPF, as well as progressive pulmonary fibrosis (PPF), causing the build-up of scar tissue in the lungs.

Both companies aim to move ahead with further trials. Vicore’s phase 2b trial will investigate FVC changes over 52 weeks, while Endeavor plans to begin the WHISTLE-PF trial, which includes a phase 2b cohort of IPF patients and a phase 2 PPF group.

If successful, both drugs could offer a disease-modifying approach to IPF.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026